Evommune Licenses China Originated VAV1 Degrader

Company Evommune; Hinova Pharmaceuticals Event Type Licensing agreement and private placement Modality Molecular glue degrader (oral) Asset EVO570 (HC118; HB570/HP570) Target VAV1 Disease Area Inflammatory and autoimmune disease Summary Evommune entered an ex-Greater-China license for Hinova’s oral VAV1 molecular glue degrader EVO570 on November 4.…